Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Patent CN104311639B details advanced solid-phase synthesis for somatostatin. Achieve higher purity and yield with optimized temperature control and resin selection.
Patent CN111825614B reveals a safer, high-yield route for gliquidone intermediates, offering significant cost and safety advantages for API manufacturers.
Novel synthesis of anti-tumor intermediates via 1,3-dipolar cycloaddition. Cost-effective scalable process for pharmaceutical manufacturing supply chains.
Patent CN1344712A details a robust telmisartan synthesis using methyl/ethyl esters, offering significant cost reduction and supply chain stability for API manufacturing.
Patent CN102115485A discloses N4-modified cytarabine prodrugs enhancing bioavailability and organ specificity for reliable pharmaceutical intermediate supply chains.
Novel chemical synthesis for L-isoleucine-L-threonine-L-aspartic acid ester. High purity, low isomers, scalable for GLP-2 production.
Novel solid-phase synthesis patent CN109456403A improves Liraglutide purity and yield. Offers cost reduction and scalable supply chain solutions for pharmaceutical manufacturers.
Novel solid-phase synthesis avoids HF and TFA. Reduces waste and cost for scalable octreotide acetate manufacturing.
Novel fragment condensation method for Liraglutide reduces costs and improves purity. Ideal for reliable API intermediate supplier partnerships.
Patent CN112979448A reveals a green synthesis route for SGLT-2 inhibitor intermediates with >99% purity and recyclable reagents.
Patent CN108976216B reveals a green, scalable route for Prucalopride intermediates, eliminating toxic reagents and ensuring high purity for global supply chains.
Discover the advanced CN1446088A process for highly purified simvastatin. Achieve superior impurity control and cost efficiency in statin manufacturing with our expert insights.
Novel ruthenium-catalyzed asymmetric hydrogenation improves yield and purity for sitagliptin intermediates ensuring cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112939994B details a novel low-loading lanthanum catalyzed method for synthesizing pyrano[2,3-b]indol-2-one scaffolds, offering significant cost reduction and scalability for pharmaceutical manufacturing.
Patent CN102206696A reveals a scalable microbial route for 11,17α-substituted pregna-1,4-diene-3,20-dione. Achieve >97% purity and reduced manufacturing costs.
Patent CN108395408B details a scalable route for [4-(1,1-difluoro-ethyl)-pyrimidine]-5-methanamine. Achieve cost reduction in API manufacturing with this efficient aqueous reduction strategy.
Novel patent CN113045504B offers high-yield dacatinib route. Reduces complexity and enhances supply chain stability for pharmaceutical manufacturing.
Novel quinoline derivatives with potent anti-influenza activity. Simple synthesis, green process, high purity. Ideal for API manufacturing cost reduction.
Patent CN102050775A details a novel method for synthesizing and isolating a critical succinimide-based impurity of Anastrozole, ensuring robust quality control and supply chain reliability for API manufacturers.
Novel asymmetric synthesis method for high-purity pharmaceutical intermediates ensuring supply chain reliability and cost reduction.